Drug
Cadonilimab clinical trials
Also written AK104.
Keep track of what changes. Save the cadonilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AK104
- 74
Studies by the year they started
158 studies that test it; most in 2023 (54)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 10 |
| 2021 | 6 |
| 2022 | 16 |
| 2023 | 54 |
| 2024 | 46 |
| 2025 | 15 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 44 · Other 114
Akeso (39) · Sun Yat-sen University (8) · Tianjin Medical University Cancer Institute and Hospital (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Fudan University (4) · Sichuan University (3) · Akesobio Australia Pty Ltd (3) · Tongji Hospital (3)
Often tested with
Tested in the same studies.
Paclitaxel (14) · Anlotinib (9) · Albumin-Bound Paclitaxel (9) · Lenvatinib (8) · Ivonescimab (8) · Carboplatin (7) · Regorafenib (5) · Disitamab vedotin (5)
Studies
Open first, then newest update. How each study uses cadonilimab is read from its arms, and is right about nine times in ten.
Testing it · 158
- FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)RecruitingPhase 3Fudan UniversityNCT07815834Written as Cadonilimab (AK104)
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingPhase 3AkesoNCT07700979Written as Cadonilimab
- A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07631000Written as Cadonilimab
- THIO and Cadonilimab in Resectable Hepatocellular CarcinomaRecruitingEarly Phase 1University of Texas Southwestern Medical CenterNCT07446257Written as Cadonilimab
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingPhase 2Tongji HospitalNCT06187961Written as Cadonilimab
- A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.RecruitingPhase 1/2Shanghai Pharmaceuticals Holding Co., LtdNCT05944224Written as Cadonilimab
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT06519591Written as Cadonilimab, LM-302, S-1, paclitaxel
- A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationPhase 1Peking University Cancer Hospital & InstituteNCT06424626Written as AK104+Axitinib
- A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male ParticipationsNot yet recruitingPhase 1AkesoNCT07619001Written as AK104 (New Site)
- Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial CarcinomaRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06532539Written as Cadonilimab
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingPhase 3AkesoNCT07412613Written as Cadonilimab (AK104)
- AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)RecruitingPhase 2Fudan UniversityNCT07544784Written as AK104 with radiotherapy
- Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard TreatmentRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05926700Written as Candonilimab
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308Written as cadonilimab
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingPhase 2AkesoNCT07052253Written as AK104
- Cadonilimab Combined With RT in LACC Patients Ineligible for CCRTNot yet recruitingPhase 2Ruijin HospitalNCT07450963Written as Cadonilimab
- A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 3AkesoNCT07449780Written as AK104(SC)
- Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingPhase 2University of Texas Southwestern Medical CenterNCT06789848Written as Cadonilimab
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingPhase 3AkesoNCT07023315Written as Cadonilimab
- IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06654011Written as Cadonilimab
See all 158 studies that test cadonilimab →
Given in every arm · 14 — cadonilimab is usual care beside what is tested
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingPhase 1/2AkesoNCT06530251Written as Cadonilimab
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingPhase 2AkesoNCT07245446Written as Cadonilimab
- AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyRecruitingPhase 2Fudan UniversityNCT06494995Written as Cadonilimab
- A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDACNot yet recruitingPhase 1AkesoNCT06913218Written as Cadonilimab
- A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic CancerRecruitingPhase 2AkesoNCT05859750Written as AK104
- Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsRecruitingPhase 1/2Zhejiang Cancer HospitalNCT06650332Written as cadonilimab
- Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesRecruitingNot applicableSun Yat-sen UniversityNCT06265350Written as Cadonilimab
- Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AkesoNCT05960955Written as Cadonilimab
- Cadonilimab With Chemotherapy in Treating Advanced Biliary CancerRecruitingPhase 2West China HospitalNCT05978609Written as Candonilimab
- Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal MetastasisActive, not recruitingPhase 1/2Guangzhou Medical UniversityNCT06762080Written as Cadonilimab (AK104)
- A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaCompletedPhase 2AkesoNCT05256472Written as AK104
- A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical CancerCompletedPhase 2AkesoNCT04868708Written as AK104
- A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaCompletedPhase 1/2AkesoNCT03852251Written as AK104
- AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCStatus unknownPhase 2Chinese Academy of Medical SciencesNCT05522894Written as AK104
As the comparator · 1 — what is tested is compared with cadonilimab
Codes
What other systems call cadonilimab · ClinicalTrials.gg INT015265
- UNII (FDA) 6FYG1DS4NWCADONILIMABOne source FDA
- NCI Thesaurus C153379CadonilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6FYG1DS4NW | CADONILIMAB | One source FDA |
| NCI Thesaurus | C153379 | Cadonilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.